Skip to main content
Quest Diagnostics

COVID-19, flu, and RSV combination testing

Know more, sooner, with respiratory molecular combination testing

SARS-CoV-2 (COVID-19), influenza, RSV, and other respiratory viruses can present with similar symptoms, such as fever, cough, and shortness of breath. For at-risk groups1-3 or patients with a more acute illness, an expedited diagnosis is crucial so that treatment can be initiated while it’s most effective.1-3 That’s why it’s important to test for each of these illnesses at the same time.

Testing that supports a faster diagnosis

When a patient presents in-office with respiratory illness symptoms, send the specimen directly to Quest for the convenience of combination testing. Our SARS-CoV-2 (COVID-19) and respiratory molecular combination tests use a single specimen to test for common respiratory viruses, providing timely results to help you develop an appropriate care plan.

Why choose SARS-CoV-2 (COVID-19) and respiratory molecular combination tests for your patients

Distinguishes between SARS-CoV-2 (COVID-19), influenza A and B, RSV, and other respiratory pathogens with just 1 swab

Eliminates the need for multiple tests or patient visits—helping to speed up the time to a diagnosis

Reduces diagnostic uncertainty and can help guide early treatment management decisions4

Highly sensitive and specific, nucleic acid amplification tests (also known as molecular tests) capable of detecting 1 or more viruses are the diagnostic “gold standard”4

Combination testing options from Quest Diagnostics

Other respiratory testing options

Panel components may be ordered separately.

References

  1. CDC. Testing for COVID-19. Updated March 10, 2025. Accessed August 17, 2026. https://www.cdc.gov/covid/testing/index.html
  2. CDC. Weekly US Influenza Surveillance Report. Updated August 16, 2024. Accessed August 17, 2026. https://www.cdc.gov/flu/weekly/index.html
  3. CDC. Clinical Overview of RSV. Updated August 18, 2025. Accessed August 17, 2026. https://www.cdc.gov/rsv/hcp/clinical-overview/index.html
  4. Hanson KE, Azar MM, Banerjee R, et al. Molecular testing for acute respiratory tract infections: clinical and diagnostic recommendations from the IDSA’s diagnostics committee. Clin Infect Dis. 2020;71(10):2744-2751. doi:10.1093/cid/ciaa508

Create a new account with Quest

Get started

COVID-19

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2026 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.